- Home
- SER vs KZR Comparison
SER vs KZR Comparison
Compare SER & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- KZR
- Stock Information
- Founded
- SER 2017
- KZR 2015
- Country
- SER United States
- KZR United States
- Employees
- SER N/A
- KZR N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- KZR Health Care
- Exchange
- SER Nasdaq
- KZR Nasdaq
- Market Cap
- SER 47.5M
- KZR 44.1M
- IPO Year
- SER 2018
- KZR 2018
- Fundamental
- Price
- SER $5.18
- KZR $4.51
- Analyst Decision
- SER Strong Buy
- KZR Hold
- Analyst Count
- SER 1
- KZR 2
- Target Price
- SER $11.00
- KZR $9.00
- AVG Volume (30 Days)
- SER 10.4K
- KZR 23.9K
- Earning Date
- SER 05-24-2025
- KZR 03-25-2025
- Dividend Yield
- SER N/A
- KZR N/A
- EPS Growth
- SER N/A
- KZR N/A
- EPS
- SER N/A
- KZR N/A
- Revenue
- SER $56,000.00
- KZR N/A
- Revenue This Year
- SER N/A
- KZR N/A
- Revenue Next Year
- SER N/A
- KZR N/A
- P/E Ratio
- SER N/A
- KZR N/A
- Revenue Growth
- SER N/A
- KZR N/A
- 52 Week Low
- SER $3.81
- KZR $4.36
- 52 Week High
- SER $14.57
- KZR $9.20
- Technical
- Relative Strength Index (RSI)
- SER 57.34
- KZR 26.49
- Support Level
- SER $4.60
- KZR $5.01
- Resistance Level
- SER $5.82
- KZR $6.37
- Average True Range (ATR)
- SER 0.40
- KZR 0.33
- MACD
- SER 0.10
- KZR -0.12
- Stochastic Oscillator
- SER 62.79
- KZR 7.46
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.